ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2025
AI-Driven Management of Type 2 Diabetes in China: Opportunities and Challenges.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Addressing Unmet Needs in the Management of Diabetes in Asia and Enhancing Diabetes Care Through the Use of Digital Technology: An Expert Opinion.Journal of the ASEAN Federation of Endocrine Societies · 2026Review
- A Scoping Review of Artificial Intelligence-Based Health Education Interventions for Patients with Type 2 Diabetes.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With the aging of China's population and lifestyle changes, the number of patients with type 2 diabetes (T2D) has surged, posing a significant challenge to the public health system. This study explores the application and effectiveness of artificial intelligence (AI) technology in T2D management from a Chinese perspective. AI demonstrates substantial potential in personalized treatment planning, real-time monitoring and early warning, telemedicine, and health management. It not only enhances the precision and convenience of treatment but also aids in preventing and managing complications. Despite challenges in data privacy, technology popularization, standardization, and regulation, AI technology's continuous maturation and expanded application suggest its increasingly pivotal role in T2D management. In the future, through interdepartmental collaboration, policy support, and cultural adaptation, AI is poised to bring revolutionary changes to diabetes management in China and globally.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.